Building Medical Device Innovations Together
Telos Partners LLC, a subsidiary of OrthoPediatrics Corp. (NASDAQ: KIDS) specializing in the strategic delivery of regulatory, reimbursement and clinician adoption services to the orthopedic, spine, and wound care industries, is pleased to announce the appointment of Jason Inzana, PhD to the position of General Manager. In this capacity, he will lead Telos in achieving […]
As an OrthoPediatrics company, Telos Partners continues to flourish! We’re pleased to announce Patrick Reischling as VP, Clinical Evidence Program. Patrick’s track record of leading industry and clinician teams through the clinical evidence pathway has earned him a stellar reputation. We are delighted to have such an accomplished professional join Telos at a time when […]
We’re proud to announce the recent publication of a new policy guideline from the International Society for the Advancement of Spine Surgery (ISASS), an international, scientific and educational society organized to discuss and assess existing strategies and innovative ideas in the clinical and basic sciences related to spine surgery to enhance patient care. Jason Inzana, […]
Telos is delighted to be a co-sponsor of an upcoming JLABS educational event on May 7th, 2020. Joel Batts, President and Co-founder of Telos, will lead expert panelists from the healthcare industry in defining the necessary steps to monetize your healthcare technology. “Cracking the Commercialization Code: 4 defining steps that could unlock your life science […]
Surgeons and clinical researchers: We are pleased to announce the call for study sites to join the Geistlich Pharma AG’s Chondro-Gide US Pivotal Trial. The study has a unique design that will evaluate outcomes of Chondro-Gide use to treat large focal knee defects. Contact us via email at secure@telospartnersllc.com. With more than 80 peer reviewed […]
In the present climate of elective surgery slowdown, now is the perfect time to establish your evidence strategy. Many approaches exist for studying medical devices, but some strategies provide faster, more affordable solutions, or more impactful data and claims. It’s critical to start with a robust understanding of the current clinical and scientific landscape related […]